Century Therapeutics, Inc. IPSC
We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Our beta islet, T cell and NK cell programs are allogeneic, meaning they are derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. As a result, we believe such "off-the-shelf" therapies have the potential to overcome the limitations of first-generation cell therapies by providing readily available treatments more quickly, reliably, at greater scale, and to a broader patient population. What we believe further sets us apart from other allogeneic approaches is our focus on induced pluripotent stem cells, or iPSCs, which possess the unique ability to self-renew indefinitely and differentiate into any cell type, enabling virtually unlimited genetic editing, consistent reproducibility, and scalable manufacturing. We have created a comprehensive, genetically engineered allogeneic cell therapy platform that includes:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M | — | — | — |
| R&D | — | — | — | — | $75.6M | $39.7M | — |
| SG&A | $24.0M | $33.2M | $34.7M | $31.9M | $19.2M | $9.5M | — |
| Total operating expenses | $126.4M | $144.7M | $148.8M | $139.0M | $94.9M | $53.9M | — |
| Operating income | -$17.3M | -$138.1M | -$146.5M | -$133.8M | -$94.9M | -$53.9M | — |
| Interest expense | — | — | $540.0K | $1.0M | $1.3M | $381.0K | — |
| Pre-tax income | -$9.6M | -$124.8M | -$134.8M | -$130.8M | -$95.8M | -$53.6M | — |
| Income tax | $68.0K | $1.8M | $1.9M | $91.0K | $43.0K | — | — |
| Net income | -$9.6M | -$126.6M | -$136.7M | -$130.9M | -$95.8M | -$53.6M | — |
| EPS, basic | -0.14 | -1.61 | -2.30 | -2.27 | -2.96 | -7.16 | — |
| EPS, diluted | -0.14 | -1.61 | -2.30 | -2.96 | -2.96 | -7.16 | — |
| Shares, diluted (wtd. avg.) | $86.6M | $78.6M | $59.3M | $32.4M | $32.4M | $7.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $61.9M | $58.4M | $49.3M | $86.2M | $58.2M | $27.7M | $44.1M |
| Short-term investments | $55.3M | $130.9M | $125.4M | $231.2M | $166.4M | $48.5M | — |
| Total current assets | $120.8M | $194.1M | $177.0M | $319.7M | $228.2M | $78.8M | — |
| Property, plant and equipment | $50.0M | $62.1M | $71.7M | $82.8M | $58.0M | $15.4M | — |
| Other intangibles | $34.2M | $34.2M | — | — | — | — | — |
| Total assets | $223.7M | $353.2M | $360.7M | $486.5M | $437.4M | $106.8M | — |
| Accounts payable | $4.8M | $3.1M | $2.7M | $5.5M | $7.6M | $8.1M | — |
| Total current liabilities | $20.2M | $129.8M | $17.8M | $29.8M | $15.7M | $12.1M | — |
| Long-term debt | — | — | — | $3.7M | $8.9M | $9.6M | — |
| Total liabilities | $64.8M | $191.9M | $175.9M | $183.8M | $41.1M | $33.4M | — |
| Retained earnings | -$791.9M | -$782.3M | -$655.8M | -$519.1M | -$388.2M | -$292.3M | — |
| Total equity | $158.9M | $161.4M | $184.8M | $302.7M | $396.2M | -$106.4M | -$91.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$103.9M | -$110.1M | -$88.3M | $14.1M | -$89.0M | -$41.3M | — |
| Depreciation and amortisation | $13.1M | $13.3M | $13.0M | $8.4M | $3.7M | $1.4M | — |
| Stock-based compensation | $6.8M | $12.7M | $14.6M | $10.7M | $4.7M | $876.0K | — |
| Capital expenditure | $848.0K | $154.0K | $13.7M | $30.6M | $45.0M | $9.8M | — |
| Investing cash flow | $107.5M | $47.5M | $61.1M | -$13.1M | -$298.3M | -$22.8M | — |
| Financing cash flow | $173.0K | $74.6M | -$9.7M | $27.2M | $417.8M | $47.7M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-026759.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |